Blog
Immuno-Oncology BioA: Pre-Existing ADAs Affecting PK
When administering human monoclonal antibodies, reconstituted human proteins, and antibody drug conjugates (ADCs), anti-drug antibodies (ADAs) can form and affect the Biotherapeutic’s exposure, bioavailability, and pharmacodynamic effects. The qualities of these ADAs – such as their specificity, magnitude, timing, maturity, and affinity – can impact pharmacokinetics (PK) and pharmacodynamics (PD). Challenges Presented by ADAs in…
Sword Bio Appoints Kara Harrison as Vice President, Quality Assurance
Sword Bio (“Sword”), a contract research organization that supports biotech and pharmaceutical companies with their bioanalytical needs for research, pre-clinical and clinical trials, announces the appointment of Kara Harrison as VP of Quality Assurance. Kara joins Sword with a proven record of leading and scaling quality management programs and initiatives. Most recently, she was VP,…